All In Biotech

Drug Trial Radar · NCT04233866

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT)

Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 176 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

176

Actual

Start

Aug 26, 2020

Primary completion

Mar 2, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
ECOG-ACRIN Cancer Research GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Jan 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial compares two treatment combinations: gemcitabine hydrochloride and nab-paclitaxel, or fluorouracil, leucovorin calcium, and liposomal irinotecan in older patients with pancreatic cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as gemcitabine hydrochloride, nab-paclitaxel, fluorouracil, leucovorin calcium, and liposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This study may help doctors find out which treatment combination is better at prolonging life in older patients with metastatic pancreatic cancer.

Conditions

  • Metastatic Pancreatic Adenocarcinoma
  • Stage IV Pancreatic Cancer AJCC v8

Interventions

  • FluorouracilDrug

    Given IV

  • GemcitabineDrug

    Given IV

  • Gemcitabine HydrochlorideDrug

    Given IV

  • LeucovorinDrug

    Given IV

  • Leucovorin CalciumDrug

    Given IV

  • Liposomal IrinotecanDrug

    Given IV

  • Nab-paclitaxelDrug

    Given IV

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Questionnaire AdministrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Up to 2 years post treatment

Locations

760 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Thomas Hospital

    Fairhope, Alabama

  • Mobile Infirmary Medical Center

    Mobile, Alabama

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Kingman Regional Medical Center

    Kingman, Arizona

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas

  • Mission Hope Medical Oncology - Arroyo Grande

    Arroyo Grande, California

  • PCR Oncology

    Arroyo Grande, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mercy Cancer Center �� Carmichael

    Carmichael, California

  • Mercy San Juan Medical Center

    Carmichael, California

  • Community Cancer Institute

    Clovis, California

  • University Oncology Associates

    Clovis, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Mercy Cancer Center - Elk Grove

    Elk Grove, California

  • City of Hope at Irvine Lennar

    Irvine, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

  • Mercy Cancer Center - Rocklin

    Rocklin, California

  • Mercy Cancer Center - Sacramento

    Sacramento, California

  • Salinas Valley Memorial

    Salinas, California

  • Pacific Central Coast Health Center-San Luis Obispo

    San Luis Obispo, California

  • Mission Hope Medical Oncology - Santa Maria

    Santa Maria, California

  • City of Hope South Pasadena

    South Pasadena, California

  • City of Hope Upland

    Upland, California

  • Woodland Memorial Hospital

    Woodland, California

  • Penrose-Saint Francis Healthcare

    Colorado Springs, Colorado

  • Rocky Mountain Cancer Centers-Penrose

    Colorado Springs, Colorado

  • UCHealth Memorial Hospital Central

    Colorado Springs, Colorado

  • Memorial Hospital North

    Colorado Springs, Colorado

Showing 40 of 760 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.